Skip to content

MDMA research published in 2026

Page 3 of 8: studies 41 to 60 of 151, newest first. Back to the MDMA overview

Studies

MDMA and Psilocybin-Assisted Therapy in Australia: Early Real-World Prescribing, Safety Monitoring and Regulatory Developments

July 12, 2026 Octavian Brinzei

Australia became the first country to establish a national regulatory pathway permitting authorised psychiatrists to prescribe 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression (TRD) through the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme. Two and a half years after implementation,...

Dermatological manifestations associated with chemsex

Journal of the European Academy of Dermatology and Venereology July 11, 2026 Pablo Balado-Simó, E Gimeno, Josep Riera‐monroig et al.

Abstract Chemsex involves the use of psychoactive substances to facilitate or enhance sexual activity, particularly among gay, bisexual, and other men who have sex with men (GBMSM). Common substances used include methamphetamine, gamma‐hydroxybutyric acid/gamma‐butyrolactone (GHB/GBL), mephedrone, ketamine, inhaled nitrites (‘poppers’), and cocaine, all of which are linked to various...

DOI: 10.1111/jdv.70608 (opens in new tab) Ecstasy Vasculitis Recreational drug Sex organ +6

Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA

Translational Psychiatry July 11, 2026 Moira G. Semple, Sarah E. Mennenga, Ryan Smith et al.

Psychoplastogen compounds such as ketamine and MDMA have shown therapeutic promise for mood and trauma-related disorders, yet the molecular mechanisms underlying their effects remain poorly understood. Here, we applied a Brain-Epigenome-Wide Association Study (BEWAS) targeting brain-relevant genes to examine DNA methylation changes following treatment. Pre- and post-treatment blood (ketamine, N...

Changes in trauma symptoms of discrimination after MDMA-assisted psychotherapy for posttraumatic stress disorder.

Scientific Reports July 11, 2026 Monnica T. Williams, Sonya C. Faber, Jordan Sloshower et al.

This preliminary study explored the effects of MDMA-assisted therapy on trauma symptoms related to discrimination, as measured by the Trauma Symptoms of Discrimination Scale (TSDS). A total of five diverse participants, who experienced multiple types of discrimination (e.g., gender, racial/ethnic, social class, age, sexual orientation), were assessed before and after treatment. A paired-samples...

Blood, beasts, ecstasy: the bodily codes of shamanism in the system of archaic biopolitics

Manuscript July 7, 2026 Elena Alekseevna Okladnikova, Alexander Mikhailovich Prilutskii

The aim of the work is to rethink the sacred functions of shamans with an emphasis on the social functions that shamans/ritualists performed in primitive and then traditional societies, and not only on the mystical content of early forms of religious ideas described by ethnologists and art historians. The article implements a theoretical transfer of the postulates of biopolitics (M. Foucault,...

α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in mice.

Molecular Psychiatry July 7, 2026 Axel F. Rosado, Abigail L. Yu, Jen-Hau Yang et al.

Classic serotonergic psychedelics such as psilocybin act as agonists at cortical serotonin (5-HT) 2A receptors (5-HT 2A R), inducing psychedelic effects in humans and head-twitch responses (HTRs) in rodents. Another class of psychedelic drugs called entactogens, exemplified by MDMA, function primarily as monoamine releasers and typically evoke minimal HTR despite causing serotonin release. The...

Open MDMA: An Evidence-Based Synthesis, Theory, and Manual for MDMA Therapy Based on Memory Reconsolidation, Complex Systems, and the Defense Cascade

July 5, 2026 Mark Groeneveld preprint

MDMA therapy is not approved by most medical regulators. But underground use is popular despite a severe lack of adequate practical guidance. Thus, I provide comprehensive practical guidance for solo and guided MDMA therapy based on critical literature synthesis, personal experience, community reports, and a mechanistic framework. I primarily address the individual doing or seeking MDMA therapy...

DOI: 10.31234/osf.io/aps5g_v6 (opens in new tab) Defense cascade Memory reconsolidation MDMA-Assisted Psychotherapy MDMA-Assisted Therapy +3

EFICÁCIA COMPARATIVA DE PSICODÉLICOS (PSILOCIBINA E MDMA) NO TRATAMENTO DE TRANSTORNO DE ESTRESSE PÓS-TRAUMÁTICO E DEPRESSÃO RESISTENTE AO TRATAMENTO: REVISÃO SISTEMÁTICA

Asclepius International Journal of Scientific Health Science July 5, 2026 Pedro Martins Rabelo

Objetivo: Avaliar a eficácia e a segurança comparativas da psilocibina e do MDMA (3,4-metilenodioximetanfetamina) no tratamento de pacientes com transtorno de estresse pós-traumático (TEPT) e depressão resistente ao tratamento (DRT), com base na evidência disponível de ensaios clínicos randomizados e estudos controlados. Métodos: Revisão sistemática conduzida segundo as diretrizes PRISMA 2020....

DOI: 10.70779/aijshs.v5i7.572 (opens in new tab) MDMA Depression economics Qualitative analysis Significant difference +2

Sexual identity as a moderator of associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes: An exploratory analysis of a nationally representative sample using NSDUH 2015–2019

Research Square July 2, 2026 Maya Seale preprint

Abstract Purpose Lifetime MDMA/ecstasy and psilocybin use have been associated with lower odds of psychological distress, suicidality, and depressive episodes, but these associations may vary by marginalized identity. Building on minorities' diminished psychedelic returns (MDPR) framework and extending Jones and Nock's race/ethnicity moderation work, this study tests whether sexual identity...

MDMA-assisted therapy for post-traumatic stress disorder: Pharmacology, mechanisms, clinical evidence, safety, and future directions

International Journal of Pharmaceutical Sciences and Drug Analysis July 1, 2026 Pratiksha Hagare, Sudarshan Nagrale, Ketana Jadhav et al.

Background: Post-traumatic stress disorder (PTSD) remains difficult to treat; a substantial proportion of patients do not respond to first-line trauma-focused psychotherapy or to sertraline and paroxetine. 3,4-Methylenedioxymethamphetamine (MDMA), a synthetic substituted amphetamine classified as an entactogen, has been studied for more than two decades as a pharmacological adjunct to...

Changes in neuroticism and values after naturalistic use of psychedelics and MDMA: a prospective survey study

Journal of Affective Disorders Reports July 1, 2026 Abigail E. Calder, Vincent J Diehl, Bernd Hinney et al.

Background Serotonergic psychedelics and MDMA may improve mental health through reductions in neuroticism and changes in personal values. While decreases in neuroticism following serotonergic psychedelics are sometimes observed, it is unclear which facets of neuroticism respond the most, and MDMA remains understudied. People also report value shifts after psychedelic experiences, but...

DOI: 10.1016/j.jadr.2026.101127 (opens in new tab) Neuroticism Survey research Personality Naturalistic observation +3

Making a case for using MDMA-assisted psychotherapy for borderline personality disorder and complex PTSD: a descriptive systematic review of the literature

Therapeutic Advances in Psychopharmacology July 1, 2026 Karthika Kasiviswanathan, Dinuli Nilaweera, M Morando et al.

Background: 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) has demonstrated considerable efficacy in treating post-traumatic stress disorder (PTSD). PTSD and complex PTSD (CPTSD) frequently co-occur with borderline personality disorder (BPD), a complex disorder marked by emotional dysregulation, interpersonal difficulties and abandonment fears - often accompanied by...

DOI: 10.1177/20451253251408626 (opens in new tab) Ecstasy Borderline personality disorder Psycinfo Abandonment legal +10

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.

Neuropsychopharmacology July 1, 2026 Denis Arikci, Joran Borgulya, Isabelle Straumann et al. 1 citation

Based on its in vitro profile and preliminary evidence, 4-bromo-2,5-dimethoxyphenethylamine (2C-B) may have psychoactive properties that are similar to 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin, which are investigated for the treatment of posttraumatic stress disorder and depressive disorders. We compared acute effects of 2C-B (10, 20, and 30 mg), 125 mg MDMA, and 25 mg psilocybin...

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

Psychopharmacology July 1, 2026 Sarah Ann Smith, Haseeb Mohammad, Lik Hang N Lee et al.

Interest in psychedelic drugs has increased rapidly because of their potential therapeutic role in psychiatric disorders. Impairments in the sociocognitive skills needed to build and maintain social relationships are prominent features of many psychiatric and neurodevelopmental disorders. Emerging evidence suggests that compounds such as 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid...

DOI: 10.1007/s00213-026-07110-y (opens in new tab) Full text (opens in new tab) Psychedelic drugs Scoping review Social cognition

MDMA-assisted PTSD and Alcohol Therapy Trial (MPATHY): study protocol for a double-blind, randomised, controlled outpatient trial of MDMA-assisted integrated exposure-based therapy for comorbid post-traumatic stress disorder and alcohol use disorder

BMJ Open July 1, 2026 Kirsten Morley, Shalini Arunogiri, Katherine L. Mills et al.

INTRODUCTION: The treatment of comorbid post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) is significantly more challenging than the treatment of either disorder alone. While gold standard evidence-based treatments exist for this comorbidity, clinically significant improvements are only observed in approximately half of clinical trial participants. The use of adjunctive...

Consumo recreativo de MDMA: un estudio sobre jóvenes en España

Escritos de Psicología / Psychological Writings June 29, 2026 Diego Fernández Piedra, A. López, Enrique Gallego-Granero et al.

Introduction: MDMA use among young people in Spain is shaped by psychosocial factors that guide consumption patterns, motivations, and risk-reduction strategies. Objective: To investigate consumption patterns, risk perception, and consumption management (strategies and practices aimed at regulating use) in recreational contexts among young people in Spain. Method: A mixed-methods design was...

DOI: 10.24310/escpsi.19.1.2026.21454 (opens in new tab) MDMA Consumption sociology Psychosocial Focus group +6

Psychometric validation of the French version of the five-dimensional altered states of consciousness questionnaire (5D-ASC) and associated 11 OAV subscales.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 20, 2026 Ewen Kervadec, Pauline Mathieu, Baptiste Fauvel et al.

The renewal of psychedelic medicine has garnered significant scientific interest, with large efforts dedicated to the understanding of the complex subjective experiences induced by these substances. The Altered States of Consciousness (ASC) questionnaire represents the most comprehensive instrument for measuring such experiences yet lacks a validated French translation despite its centrality to...

Protocol for a qualitative mechanistic study of MDMA with a sample of psychoanalytic psychotherapists: A phenomenological investigation

PLoS One June 18, 2026 Elisa Liberati, Hv Curran, Peter Fonagy et al.

INTRODUCTION: Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) is a potentially transformative intervention for post-traumatic stress disorder (PTSD). Despite encouraging Phase III trial results, the psychological mechanisms underpinning MDMA's therapeutic effects remain insufficiently understood. Existing research on MDMA has emphasised neurobiological processes but has...

DOI: 10.1371/journal.pone.0350728 (opens in new tab) MDMA Grounded theory Interpretative phenomenological analysis Thematic analysis +14

MDMA-induced CYP2D6 inhibition: concentration-dependent variability using dextromethorphan as a probe

Drug Metabolism and Personalized Therapy June 16, 2026 Faezeh Ahmadi, Hoda Lavasani, Mohammadhosein Keshvadi et al.

OBJECTIVES: Ecstasy is commonly abused due to entactogenic effects. Although our previous studies on isolated perfused rat model confirmed inhibition of CYP2D6 by MDMA, the time for enzyme recovery was different when mirtazapine and tramadol were used as substrates. Therefore, present study intended to investigate CYP2D6 inhibition by MDMA using dextromethorphan as a well-known probe. Two...